Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether ...

(Reuters) - Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

A Swiss drug giant has gotten the message from President Trump’s tariff threats. Novartis said Thursday it will spend $23 ...

Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S.

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

It joins a growing number of multinational drug companies to announce investments in the US. Read more at straitstimes.com.

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis knee pain. The Big Pharma company discontinued the study testing intra ...